KRSA · Korsana Biosciences, Inc. · Executive Compensation
$30.00
-0.22 (-0.73%)
At close · Oct 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 4, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Market Cap
$20.21M
Shares
668,764
Volume · Oct 30
3732
Avg daily vol (37 sessions)
114.65K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Cheryl Gault | Chief Operating Officer | $644,606 |
| Anjeza Gjino | Chief Financial Officer and Corporate Secretary | $625,421 |
| Peter M. Hecht | Ph.D., Chief Executive Officer | $590,257 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Andreas Busch | Ph.D.,^\ ^ Chief Scientific Officer | $782,544 |
| Cheryl Gault | Chief Operating Officer | $664,345 |
| Peter M. Hecht | Ph.D., Chief Executive Officer | $108,220 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Andreas Busch | Ph.D.,^\ ^ Chief Scientific Officer | $806,919 |
| Christopher Wright | M.D., Ph.D, Chief Medical Officer | $767,080 |
| Peter M. Hecht | Ph.D., Chief Executive Officer | $365,993 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Andreas Busch | Ph.D.,\ Chief Scientific Officer | $3,251,107 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Andrew Gottesdiener | member of the Audit Committee | Appointed | 2026-09-11 |
| Tomas Kiselak | Chair of the Board | Appointed | 2026-09-11 |
| Nimish Shah | Board | Appointed | 2026-09-11 |
| Jonathan Violin, Ph.D. | Board | Appointed | 2026-09-11 |
| Michelle Pernice | Board | Appointed | 2026-09-11 |
| Heidi Henson | Board | Appointed | 2026-09-11 |
| Tomas Kiselak | Board | Appointed | 2026-09-11 |
| Andrew Gottesdiener, M.D. | Board | Appointed | 2026-09-11 |
| Mark Vignola, Ph.D. | Chief Financial Officer | Appointed | 2026-09-11 |
| Matthew Leoni, M.D. | Chief Medical Officer | Appointed | 2026-09-11 |
| Jonathan Violin, Ph.D. | Chief Executive Officer and President | Appointed | 2026-09-11 |
| Rhonda M. Chicko | Chief Financial Officer | Resigned | 2026-09-11 |
| Regina M. Graul, Ph.D. | President and Chief Executive Officer | Resigned | 2026-09-11 |
| Steven E. Hyman, M.D. | board of directors | Resigned | 2026-09-11 |
| Dina Katabi, Ph.D. | board of directors | Resigned | 2026-09-11 |
| Michael Higgins | board of directors | Resigned | 2026-09-11 |
| Peter M. Hecht, Ph.D. | board of directors | Resigned | 2026-09-11 |
| Regina M. Graul, Ph.D. | board of directors | Resigned | 2026-09-11 |
| Errol B. De Souza, Ph.D. | board of directors | Resigned | 2026-09-11 |
| Peter Hecht, Ph.D. | President and Chief Executive Officer | Resigned | 2023-12-04 |
| Regina Graul Ph.D. | President | Appointed | 2023-12-04 |
| Dina Katabi, Ph.D. | Board of Directors | Appointed | 2023-12-01 |
| Michael Higgins | Board of Directors | Appointed | 2023-12-01 |
| Ole Isacson, M.D., Ph.D. | director | Resigned | 2023-11-24 |
| Cheryl Gault | Chief Operating Officer | Resigned | 2023-06-27 |
Leadership
- Jonathan Violin, Ph.D. CEO, Board Member
- Regina M. Graul CEO, Board Member
- Tomas Kiselak Chairman, Board Member
- Anjeza Gjino CFO
- Mark Vignola, Ph.D. CFO
- Peter M. Hecht CFO, Board Member
- Andrew Gottesdiener Board Member
- Andrew Gottesdiener, M.D. Board Member
- Dina Katabi Board Member
- Dina Katabi, Ph.D. Board Member
- Heidi Henson Board Member
- Michael F. Higgins Board Member
- Michael Higgins Board Member
- Michelle Pernice Board Member
- Nimish Shah Board Member
- Steven E. Hyman Board Member
- Steven E. Hyman, M.D. Board Member